This document provides information about a two-day hematologic cancers training program taking place in Newark, NJ in October 2017. The program will review the hematological system and provide an overview of hematologic cancers such as leukemias, lymphomas and myeloma. Experts will discuss the pathophysiology, common treatments, management challenges and complications like bone marrow transplant. Case studies and discussion are included. The program is intended for pharmaceutical and biotech personnel. Topics will include blood cell formation/maturation, cancer classification/epidemiology, diagnosis/staging, chemotherapy and clinical trials.

1. www.healthtech.com/hematologic-cancers
PROGRAM OUTLINE:
Hematologic Cancers – An Introduction
October 24-25, 2017
Newark Liberty International Airport Marriott - Newark, NJ
www.healthtech.com/hematologic-cancers
This course reviews the hematological system and provides an overview on the spectrum of
hematologic cancers. The expert teaching team, comprising currently practising physicians, guides
course attendees through the pathophysiology of Hematologic Cancers - An Introduction such as
leukemias, lymphomas and myeloma. Common treatments and management of these malignancies
are discussed as well as the challenges these treatments present to patients. The issues and
complications of bone marrow and stem cell transplant are also reviewed. Case studies and open
discussion form an integral part of the program.
Who should attend?
This hematological cancers training is designed to meet the broad information and education
requirements of a range of pharmaceutical and biotech personnel from R&D, medical affairs,
regulatory, strategic marketing and and many others from both science and business functions.
Topics to be covered include:
• The formation and maturation of blood cells
• Classification and epidemiology of hematological malignancies
• Presentations, diagnosis and staging
• Chemotherapy and irradiation
• Clinical trial issues
Faculty includes:
• Dennis Cooper, M.D., Professor of Medicine (Hematology), Yale School of Medicine
• Louis F. Diehl, M.D., Associate Professor of Medicine & Oncology, Director, Myeloma
Program, Division of Hematological Malignancies, John Hopkins Sidney Kimmel Comprehensive
Cancer Center
• Carol Ann Huff, M.D., Associate Professor of Medicine and Oncology, Director, Myeloma
Program, Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center
• Mark Levis, M.D., Associate Professor of Oncology, Pharmacology, and Medicine at Sidney
Kimmel Comprehensive Cancer Center
• Douglas Smith, M.D., Associate Professor, Hematologic Malignancies, Sidney Kimmel
Comprehensive Cancer Center
Administrative/Venue Details:
The registration fee at CHI’s VIP Discount Rate is $4,495 USD (regular rate $4,995 USD). You save 10%
off your registration by registering through our marketing partner, Cambridge Healthtech Institute
(CHI). This includes lunch and refreshments throughout the day. Accommodation costs are not included
in the course fee. However, Healthcare has organized a special bed and breakfast rate the venue who

2. www.healthtech.com/hematologic-cancers
require overnight accommodation – details of how to book will be provided with the joining instructions for
the course.
Delegates can register on-line or by completing the booking form and returning it together with the
appropriate payment to Cambridge Healthtech Institute. Please retain a copy of the booking form for your
records. Details of the venue will be supplied on registration.
PROGRAM AGENDA
Tuesday, October 24 (8:45 am – 4:20 pm)
Registration – Continental breakfast available
Welcome/Opening remarks
Introduction / Overview
• Review – Hemopoiesis
- terminology and concepts
- control of hemopoiesis
 +ve and –ve regulators
• Classification and epidemiology of liquid tumors
- pre-leukemias
- chronic leukemias
 CLL
 CML
- acute leukemias
 AML
 ALL
- Myeloma
• Chemotherapy overview
- Flow cytometry
- immunohistochemistry
Discussion
Tea/coffee break
Stem Cell Transplantation
• Autologous / allogenic
- conditioning regimes
- indications
- complications (e.g. graft versus host disease)
Stem Cell Transplantation Discussion
LUNCH

3. www.healthtech.com/hematologic-cancers
CLL
• Clinical presentation
• Diagnosis and staging
• Treatment options
• Disease course and progression
CLL Case Studies and Discussion
Tea/coffee break
CML
• Clinical presentation
• Diagnosis and staging
• Treatment options
• Disease course and progression
CML Case Studies and Discussion
4:20 pm End of Day One
Wednesday, October 25 (8:30 am – 3:45 pm)
The Lymphomas
• Hodgkin’s disease /Non-Hodgkin’s lymphoma
- epidemiology / genetics
- clinical presentation
• Treatment and prognosis
The Lymphomas Case Studies and Discussion
Tea/coffee break
Acute Leukemias
• AML and ALL
• Clinical presentations
• Diagnosis
• Chromosomal abnormalities
• Treatment options
• Prognosis
Acute Leukemias Case Studies and Discussion
LUNCH

4. www.healthtech.com/hematologic-cancers
Myelodysplasia and Myeloproliferation
• Clinical presentation
• Diagnosis and staging
• Treatment options
• Disease course and progression
Myelodysplasia and Myeloproliferation
Case Studies and Discussion
Tea/coffee break
Myeloma
• Clinical presentation
• Diagnosis and staging
• Treatment options
Myeloma Case Studies and Discussion
3:45 pm CLOSE
About the Instructors:
Dennis L. Cooper, M.D.
Professor of Medicine (Hematology)
Yale Cancer Center
Dennis Cooper, M.D., is a Professor of Internal Medicine (Hematology) at the Yale School of Medicine.
Following graduation from Rush Medical School, he completed his residency in Internal Medicine at
Yale-Newhaven Hospital followed by a chief residency at the University of Pittsburgh. He returned to
Yale for his fellowship training and then served as Fellowship Director and Clinical Director of the
Hematopoietic Stem Cell Transplant Service. His clinical interests are recurrent lymphoma, multiple
myeloma, and hematopoietic stem cell transplantation.
Louis F. Diehl, M.D.
Associate Professor of Medicine & Oncology, Director, Myeloma Program, Division of Hematological
Malignancies, John Hopkins Sidney Kimmel Comprehensive Cancer Center
Dr. Diehl graduated from Georgetown University in 1970 with a BS in physics, where during research
projects applying physical measurement techniques to biological materials, he developed his first
interest in medicine. He graduated from Georgetown University Medical School, in 1975, and entered
active duty in the Army while completing an internal medicine residency (1978) at Walter Reed and
subsequent fellowship in Hematology-Oncology (1981). His initial research work centered on
Hodgkin’s lymphoma with subsequent work in the understanding of the treatment of non-Hodgkin’s
lymphoma. Throughout his career he has maintained a strong interest in the bias inherent in clinical
studies and how they can lead us to truth or folly. He has been a division director, program director in
both internal medicine and Hematology-Oncology, and a Chairman, Department of Medicine. After
leaving the Army in 1999, he went to Johns Hopkins where he worked in the division of Hematologic
Malignancies. He has been at Duke University Medical Center since 2004, directs the Oncology
Treatment Center and actively treats patients with Hematologic Malignancies.
Areas of Interest:
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Chronic leukemias
- Acute leukemias
- Multiple myeloma

5. www.healthtech.com/hematologic-cancers
- Myelodysplasia
Research Interests:
- staging and treatment of Non-Hodgkin lymphoma
- long term care of patients with Hodgkin disease
- Bias in clinical trials
Associations:
- American Society of Hematology
- American Society of Clinical Oncology
- Cancer and Leukemia Group B
- American College Physicians
- Alpha Omega Alpha
Carol Ann Huff, M.D.
Associate Professor of Medicine and Oncology,
Director, Myeloma Program, Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
Carol Ann Huff, MD, is an Assistant Professor of Oncology and Medicine at the Johns Hopkins
University School of Medicine in Baltimore, Maryland, where she is also the Director of the Myeloma
Program in the Division of Hematologic Malignancies.
Dr. Huff's research interest is in developing novel biologically-based therapies for myeloma including
attempts to target myeloma stem cells and immune-based approaches. Her efforts have focused on
improving response rates and overall survival for patients with multiple myeloma as well as reducing
the toxicity of bone marrow transplantation coupled with efforts to develop a targeted immune attack
post-transplantation.
Prior to receiving her medical degree from Baylor College of Medicine, Dr. Huff completed a Bachelor
of Science in Zoology at Duke University in Durham, NC. She completed her internship and residency
at the Johns Hopkins University School of Medicine before joining the Department of Medicine as an
Instructor where she was later promoted to Assistant Professor. Dr. Huff went on to complete a
clinical fellowship in Oncology before formally accepting a joint appointment in the Oncology
department.
Dr. Huff has authored many peer-reviewed articles, book chapters, and monographs in the field of
myeloma research and is a leading national speaker on this topic.
Mark Levis, M.D., Ph.D.
Associate Professor of Oncology, Pharmacology, and Medicine
Sidney Kimmel Comprehensive Cancer Center
Mark Levis, M.D., Ph.D., has been Member of the Hematology and Oncology Clinical Advisory Board of
Ambit Biosciences Corporation since February 28, 2008. Dr. Levis serves as Assistant Professor at
Johns Hopkins University in Baltimore. Mr. Levis laboratory research focuses on the development of
molecularly targeted therapies for leukemia. Currently, he is actively involved in the pre-clinical and
clinical development of small molecule inhibitors of the receptor tyrosine kinase, FLT3. He served as
Member of Scientific Advisory Board at Symphogen A/S.
Publications
Levis, M., Tse, K-F., Smith, B.D., Garrett, E., and Small, D. (2001). A FLT3 tyrosine kinase inhibitor is
cytotoxic to AML blasts harboring a FLT3/ITD mutation. Blood. 98:885.
Levis, M., Allebach, J., Tse, K-F., Sheng, R., Baldwin, B.R., Smith, B.D., Jones-Bolin, S., Ruggeri, B.,
Dionne, C., and Small, D. (2002). A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia
cells in vitro and in vivo. Blood 99:3885.

6. www.healthtech.com/hematologic-cancers
Smith, B.D., Levis, M., Beran, M., Giles, F., Brown, P., Russell, L., Hellriegel, E., Murphy, K., Dauses,
T., Allebach, J., and Small, D. (2004) Single agent CEP-701, a novel FLT3 inhibitor, shows initial
response in patients with refractory acute myeloid leukemia. Blood. 103:3669
Levis, M. and Small, D. (2003). FLT3:ITDoes matter in leukemia. Leukemia. 17:1738.
Murphy, K.M., Levis, M., Hafez, M.J., Geiger, T., Cooper, L.C., Smith, B.D., Small, D., and Berg, K.D.
(2003). Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase
chain reaction and capillary electrophoresis assay. J Mol Diagn. 5: 96-102.
Zheng, R., Levis, M, Piloto O, Brown P, Baldwin B., and Small, D. (2003) FLT3 ligand (FL) causes
autocrine signaling in AML cells. Blood. 103:267.
Levis, M., and Small, D. (2004). Small molecule FLT3 tyrosine kinase inhibitors. Current
Pharmaceutical Design. 10:1183.
B. Douglas Smith, M.D.
Associate Professor, Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
Dr. Smith graduated from Drexel University College of Medicine in 1991. Dr. Smith’s expertise
includes acute lymphoblastic leukemia, acute myeloid leukemia, blood transplant, bone marrow
transplant, chronic myeloid leukemia, drug development, hematologic malignancies, leukemia,
medical oncology, myelodysplasia, myelodysplastic syndrome, myeloproliferative disorders. His
research interests include acute and chronic leukemias; myeloid disorders and bone marrow
transplantation.
B. Douglas Smith, MD, received his medical degree from the Medical College of Pennsylvania in
Philadelphia, Pennsylvania, followed by internship, residency, and a Chief Residency in Internal
Medicine at the University of Rochester’s Strong Memorial Hospital. Dr. Smith went on to complete his
Oncology Fellowship at The Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr.
Smith joined the faculty at Johns Hopkins upon completion of his training and is now an Associate
Professor of Oncology.
Dr. Smith’s research focuses on taking new and promising laboratory insights and developing them
into biology based treatment approaches for patients with myeloid malignancies. He has developed
close laboratory collaborations and has focused on the clinical development of three main areas:
cancer stem cell biology and differentiation-based treatment approaches, signal transduction and
targeted drug development, and immunotherapy using vaccine strategies.
Clinically, Dr. Smith’s interests center on treating patients with myeloid malignancies, including acute
and chronic myeloid leukemias, and myelodysplastic syndromes. He is recognized as a national leader
in these areas and serves on the NCCN Guideline Panel for both AML and CML. Dr. Smith also supports
the SKCCC at Johns Hopkins through his participation on the Johns Hopkins Institutional Review
Board.
How to Register:
Web: https://chidb.com/reg/hes/hcp-reg.asp
Call: 781-972-5400
Email: reg@healthtech.com
Group Discounts are Available!
Organizations sending 2 or more individuals qualify for a group discount. For details, contact:
David Cunningham, Tel: 781-972-5472, cunningham@healthtech.com.

7. www.healthtech.com/hematologic-cancers
Course Registration Form
Hematologic Cancers – An Introduction
October 24-25, 2017
Newark Liberty International Airport Marriott - Newark, NJ
Fill out and fax back to Kris Waterman at +1 781-972-5425.
If you are paying by check or have any questions regarding payment, please call +1 781-
972-5400. To inquire about a group discount, call +1 781-972-5472 or email
cunningham@healthtech.com
Fee: VIP Discount Rate $4,495 USD (regular rate $4,995 USD). Hotel and travel costs are not included.
YOUR DETAILS:
Title: (tick applicable) __ Dr. __ Mr. __ Mrs. __ Ms. __ Miss __ Other
_________________________________________________________________
First Name Last Name
_________________________________________________________________
Company Job Title
_________________________________________________________________
Department Address
_________________________________________________________________
City State Country
_________________________________________________________________
Telephone Fax Email
Charge my credit card
___ VISA ___MasterCard ___American Express
________________________________________________
Name (as it appears on card)
________________________________________________
Account Number
_______________________________________________
Start Date (mm/yy) End Date (mm/yy)
_______________________________________________
Security Number (from rear/front of card)
_______________________________________________
Signature
Please note: No refund/credit of registration fee will be made for any cancellations received less than 20 working days prior to the date of the course. Cancellations made more
than 20 working days prior to course date will incur a $175 (USD) administration fee. Substitutions may be made at any time. If Healthcare cancels or postpones this event, the
registration fee will be refunded. Healthcare will not accept liability for any other costs. Healthcare reserves the right to amend the content and timing of all courses. Your details
will be entered onto our database and we may, from time to time, advise you of other products that may be of interest to you. If you do not wish to receive this information then
please let us know.